Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease

NCT03019536 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03019536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03019536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2017
Completion date
June 5, 2019
Enrollment
22 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease